DiaMedica Therapeutics (DMAC) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on therapies for preeclampsia (PE) and acute ischemic stroke (AIS), with lead candidate DM199 (rinvecalinase alfa), a recombinant human tissue kallikrein-1 protein in global clinical development for both indications.

• DM199 is designed to address critical unmet needs in PE and AIS, with Fast Track designation from the FDA for AIS and a unique mechanism that may avoid fetal exposure in PE.

• Pipeline includes DM199 in Phase 2/3 trials for AIS and PE, and DM300, a preclinical candidate for severe acute pancreatitis.

• DM199 is produced using recombinant DNA technology, eliminating risks associated with animal or human tissue-derived products.

Financial performance and metrics

• As of June 30, 2025, net tangible book value was $27.2 million, or $0.63 per share, with 43,072,488 shares outstanding.

• After a $100 million offering at $4.58 per share, pro forma net tangible book value would be $127.2 million, or $1.96 per share, resulting in immediate dilution of $2.62 per share to new investors.

• Common shares have traded between $2.16 and $6.82 per share from January 2024 to June 2025, with daily trading volume ranging from 24,100 to 3,185,200 shares.

Use of proceeds and capital allocation

• Net proceeds will be used to advance clinical and product development activities for DM199 in preeclampsia and for general corporate purposes.

• Management has broad discretion over the use of funds, which may also be allocated to other working capital needs.

• Pending use, proceeds may be held in non-interest bearing accounts or invested in short-term securities.